US Stock MarketDetailed Quotes
GDTC CytoMed Therapeutics
- 2.305
- -0.105-4.36%
Close Nov 1 16:00 ET
- 2.400
- +0.095+4.12%
Post 17:38 ET
26.60MMarket Cap-11135P/E (TTM)
2.450High2.277Low1.48KVolume2.450Open2.410Pre Close3.46KTurnover0.04%Turnover RatioLossP/E (Static)11.54MShares5.50052wk High3.46P/B8.17MFloat Cap1.20052wk Low--Dividend TTM3.55MShs Float9.250Historical High--Div YieldTTM7.18%Amplitude1.200Historical Low2.341Avg Price1Lot Size
CytoMed Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||
| Gross profit | ||||
| Operating expense | 106.99%3.84M | 7.43%1.86M | 37.57%1.73M | 1.26M |
| Selling and administrative expenses | 223.37%1.28M | 36.32%397.11K | 47.87%291.32K | --197.01K |
| -Selling and marketing expense | --33.31K | --0 | -59.87%2.48K | --6.18K |
| -General and administrative expense | 214.98%1.25M | 37.49%397.11K | 51.36%288.84K | --190.83K |
| Research and development costs | 4.40%1.59M | 39.62%1.52M | 5.06%1.09M | --1.04M |
| Depreciation amortization depletion | -6.88%104.05K | 10.38%111.75K | 16.86%101.23K | --86.63K |
| -Depreciation and amortization | -6.88%104.05K | 10.38%111.75K | 16.86%101.23K | --86.63K |
| Other taxes | -5.45%6.66K | 72.63%7.05K | 17.17%4.08K | --3.48K |
| Other operating expenses | 571.33%858.3K | -175.58%-182.1K | 449.36%240.93K | ---68.96K |
| Operating profit | -106.99%-3.84M | -7.43%-1.86M | -37.57%-1.73M | -1.26M |
| Net non-operating interest income expense | 290.48%234.44K | -7.65%-123.08K | -8.35%-114.33K | -105.52K |
| Non-operating interest income | 13,525.13%285.72K | -37.76%2.1K | --3.37K | --0 |
| Non-operating interest expense | -59.03%51.28K | 6.35%125.18K | 11.54%117.7K | --105.52K |
| Other net income (expense) | 54.43%-524.11K | -449.29%-1.15M | 63.51%-209.39K | -573.86K |
| Gain on sale of security | -1,391.77%-394.16K | -178.68%-26.42K | -2,089.61%-9.48K | ---433 |
| Earnings from equity interest | 7.00%-31.2K | 84.22%-33.55K | ---212.58K | --0 |
| Special income (charges) | --0 | --280 | --0 | --0 |
| -Gain on sale of property,plant,equipment | --0 | --280 | --0 | --0 |
| Other non- operating income (expenses) | 90.94%-98.75K | -8,709.51%-1.09M | 102.21%12.67K | ---573.42K |
| Income before tax | -32.04%-4.13M | -52.53%-3.13M | -6.01%-2.05M | -1.94M |
| Income tax | -60.18%653 | 1.64K | 0 | 0 |
| Net income | -31.99%-4.13M | -52.61%-3.13M | -6.01%-2.05M | -1.94M |
| Net income continuous Operations | -31.99%-4.13M | -52.61%-3.13M | -6.01%-2.05M | ---1.94M |
| Minority interest income | -12.76%-274 | 3.95%-243 | -36.02%-253 | -186 |
| Net income attributable to the parent company | -31.99%-4.13M | -52.62%-3.13M | -6.00%-2.05M | -1.94M |
| Preferred stock dividends | ||||
| Other preferred stock dividends | ||||
| Net income attributable to common stockholders | -31.99%-4.13M | -52.62%-3.13M | -6.00%-2.05M | -1.94M |
| Basic earnings per share | -36.26%-0.39 | -52.62%-0.2862 | -6.00%-0.1875 | -0.1769 |
| Diluted earnings per share | -36.26%-0.39 | -52.62%-0.2862 | -6.00%-0.1875 | -0.1769 |
| Dividend per share | ||||
| Currency Unit | SGD | SGD | SGD | SGD |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data